Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 19/20 | 1.00 |
| ▸ | WNT1 | P04628 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23198185 | 1.00 | USP30 (1.00) | USP30WNT1GSK3BDYRK1A | |
| SCHEMBL23198181 | 1.00 | USP30 (1.00) | USP30WNT1GSK3BDYRK1A | |
| SCHEMBL19281707 | 0.86 | USP30 (0.75) | USP30WNT1GSK3BDYRK1A | |
| SCHEMBL19281705 | 0.86 | USP30 (0.75) | USP30WNT1GSK3BDYRK1A | |
| SCHEMBL29992732 | 0.86 | USP30 (0.75) | USP30WNT1GSK3BDYRK1A | |
| SCHEMBL20051562 | 0.83 | USP30 (1.00) | USP30 | |
| SCHEMBL23198172 | 0.83 | USP30 (1.00) | USP30 | |
| SCHEMBL29614901 | 0.83 | USP30 (1.00) | USP30 | |
| SCHEMBL29614921 | 0.83 | USP30 (1.00) | USP30 | |
| SCHEMBL20051577 | 0.83 | USP30 (1.00) | USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109803963-B | Cyano-substituted heterocycles having USP30 inhibitor activity | 特殊治疗有限公司 | 2022-04-26 | — | — | CN | claimed |
| US-11370784-B2 | Cyano-substituted heterocycles with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| CN-109803963-B | Cyano-substituted heterocycles having USP30 inhibitor activity | 特殊治疗有限公司 | 2022-04-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370784-B2 | Cyano-substituted heterocycles with activity as inhibitors of USP30 | USP30, USP28, USP1 | USP30 1/4885WNT1 2703/4885GSK3B 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.